
TMDX Stock Forecast & Price Target
TMDX Analyst Ratings
Bulls say
TransMedics Group Inc. has demonstrated notable growth in the transplant market, with DCD (Donation After Circulatory Death) hearts and livers showing significant year-over-year increases of 15% and 44%, respectively, indicating a strong demand for their organ preservation technology. Despite some month-over-month fluctuations in liver transplant volumes, the overall growth in the DCD market contributed to a 7% increase in combined heart, liver, and lung transplants for the quarter to date. Furthermore, the company is positioned for potential upside with new product launches, increased adoption rates in lung transplants, and anticipated improvements in operating margins, suggesting a robust revenue forecast including an estimated $120M in 4Q24.
Bears say
TransMedics Group's stock faces a negative outlook due to a notable decline in donor organ transplants, with DBD livers and hearts experiencing a year-over-year drop of 6% and DBD hearts declining 12% month-over-month. Despite a slight increase in revenue estimates for 2026, recent group multiples have decreased from 7.2x to 6.8x, indicating declining investor confidence. Additionally, the company is exposed to various risks, including potential competition from metra and NRP, which could hinder its market share and slow growth, coupled with concerns regarding the adoption of its Organ Care System and possible regulatory challenges.
This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.
TMDX Analyst Forecast & Price Prediction
Start investing in TMDX
Order type
Buy in
Order amount
Est. shares
0 shares